This Article Full Text Full Text (PDF) All Versions of this Article: 200507-1072OCv1 172/11/1457    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenthal, I. M. Articles by Nuermberger, E. L. Search for Related Content PubMed PubMed Citation Articles by Rosenthal, I. M. Articles by Nuermberger, E. L.

Weekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis

Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, and Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia; and Infectious Diseases Pharmacokinetics Laboratory, National Jewish Medical and Research Center, Denver, Colorado

Correspondence and requests for reprints should be addressed to Eric L. Nuermberger, M.D., 1503 East Jefferson Street, Baltimore, MD 21231–1002. E-mail: enuermb{at}jhmi.edu

Rationale: Treatment of tuberculosis with an efficacious once-weekly regimen would be a significant achievement in improving patient adherence. Currently, the only recommended once-weekly continuation phase regimen of isoniazid plus rifapentine (10 mg/kg) is inferior to standard twice-weekly therapy with isoniazid plus rifampin and is, therefore, restricted to non–high-risk patients. The substitution of moxifloxacin, a new 8-methoxyfluoroquinolone, for isoniazid and an increase in the dose of rifapentine could augment the activity of once-weekly regimens.

Methods: To test this hypothesis we evaluated the sterilizing activity of improved once-weekly rifapentine-based continuation phase regimens in a murine model that mimics the treatment of high-risk patients with tuberculosis. The bactericidal activity of standard daily therapy and standard intermittent therapy ("Denver" regimen) was also assessed to evaluate the effect of intermittent drug administration during the initial phase of therapy.

Results: After 2 mo of treatment, lung colony-forming unit counts were 1 log₁₀ lower in mice treated with standard daily therapy than with the Denver regimen. During the continuation phase, the sterilizing activity of once-weekly moxifloxacin plus rifapentine (15 mg/kg) was significantly greater than that of the predominantly twice-weekly Denver regimen of isoniazid plus rifampin. No significant difference in sterilizing activity was detected between once-weekly isoniazid plus rifapentine (15 mg/kg) and the Denver regimen.

Conclusions: These results suggest that the efficacy of the once-weekly isoniazid plus rifapentine continuation phase regimen can be increased by substituting moxifloxacin for isoniazid and by increasing the dose of rifapentine to a clinically acceptable level of 15 mg/kg.

Key Words: antibiotics • intermittent therapy • mouse • treatment

This article has been cited by other articles:

				J. van den Boogaard, G. S. Kibiki, E. R. Kisanga, M. J. Boeree, and R. E. Aarnoutse New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development Antimicrob. Agents Chemother., March 1, 2009; 53(3): 849 - 862. [Full Text] [PDF]

				N. Veziris, M. Ibrahim, N. Lounis, A. Chauffour, C. Truffot-Pernot, K. Andries, and V. Jarlier A Once-Weekly R207910-containing Regimen Exceeds Activity of the Standard Daily Regimen in Murine Tuberculosis Am. J. Respir. Crit. Care Med., January 1, 2009; 179(1): 75 - 79. [Abstract] [Full Text] [PDF]

				K. Dooley, C. Flexner, J. Hackman, C. A. Peloquin, E. Nuermberger, R. E. Chaisson, and S. E. Dorman Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations Antimicrob. Agents Chemother., November 1, 2008; 52(11): 4037 - 4042. [Abstract] [Full Text] [PDF]

				I. M. Rosenthal, M. Zhang, D. Almeida, J. H. Grosset, and E. L. Nuermberger Isoniazid or Moxifloxacin in Rifapentine-based Regimens for Experimental Tuberculosis? Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 989 - 993. [Abstract] [Full Text] [PDF]

				D. Almeida, E. Nuermberger, S. Tyagi, W. R. Bishai, and J. Grosset In Vivo Validation of the Mutant Selection Window Hypothesis with Moxifloxacin in a Murine Model of Tuberculosis Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4261 - 4266. [Abstract] [Full Text] [PDF]

				G. Tino Clinical Year in Review IV: Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Infections, and Mycobacterial Disease Proceedings of the ATS, November 1, 2006; 3(8): 650 - 653. [Full Text] [PDF]

				I. M. Rosenthal, K. Williams, S. Tyagi, C. A. Peloquin, A. A. Vernon, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger Potent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 94 - 101. [Abstract] [Full Text] [PDF]

				W. W. Yew and C. C. Leung Update in tuberculosis 2005. Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 491 - 498. [Full Text] [PDF]

				Weekly Combination Therapy for TB? Journal Watch Infectious Diseases, December 21, 2005; 2005(1221): 7 - 7. [Full Text]

				E. A. Nardell and E. J. Rubin Once upon a Time...: Improved Intermittent Therapy for Tuberculosis--Fact or Fable? Am. J. Respir. Crit. Care Med., December 1, 2005; 172(11): 1361 - 1362. [Full Text] [PDF]

				E. Nuermberger, S. Tyagi, K. N. Williams, I. Rosenthal, W. R. Bishai, and J. H. Grosset Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model Am. J. Respir. Crit. Care Med., December 1, 2005; 172(11): 1452 - 1456. [Abstract] [Full Text] [PDF]